Aquestive Therapeutics AQST 深 滬
等待開盤 09-08 09:30:00 美东时间
5.34
-0.010
-0.19%
華盛通- 最 高5.485
- 今 開5.32
- 成交量 211.78万股
- 最 低 5.29
- 昨 收 5.35
- 總市值 6.70亿
- 52周最高 7.55
- 市盈率 靜 --
- 換手率 1.69%
- 52周最低 2.93
- 委 比 34.62%
- 總股本 1.26亿
- 歷史最高 20.696
- 量 比 1.03
- 振 幅 3.64%
- 歷史最低 0.618
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics announced that its management team will participate in four investor conferences in September 2026. These include the 2026 Wells Fargo Healthcare Conference on September 8th, the Cantor Healthcare Conference with a fireside chat at 3:20 pm ET on September 9th, Citi’s 2026 Biopharma Back to School Summit on September 10th, and the H.C. Wainwright 27th Annual Global Investor Conference with a presentation at 9:00 am ET on Sep...
09-01 11:00
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains $10 price target.
08-24 18:07
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress
Aquestive Therapeutics, Inc. (($AQST)) has held its Q2 earnings call. Read on f...
08-21 08:25
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
08-12 04:01
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
08-10 21:21
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive results from human factors and pharmacokinetic studies for Anaphylm™, supporting its planned NDA resubmission in Q3 2026. Key improvements include a revised packaging design reducing pouch-opening time from 17 seconds to 3 seconds, and updated instructions reducing incorrect film placement by over 80%. Pharmacokinetic results showed comparable efficacy between self-administration and clinician-administrat...
08-10 11:00
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics will report Q2 2026 results on August 11, 2026, and host an investor conference call on August 12 at 8:00 a.m. ET. Registration is required for participation. A live webcast and replay will be available on the company’s website. Aquestive, a pharmaceutical company specializing in innovative drug delivery technologies, is advancing products like Anaphylm™ and AQST-108 for various therapeutic indications.
07-29 11:00
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that its management team will participate in the Leerink Partners Therapeutics Forum on July 14, 2026, to discuss key themes in immunology, inflammation, and metabolism, and host investor meetings. The company, a leader in oral film medications, develops innovative therapies like Anaphylm™ for severe allergic reactions and AQST-108 for dermatological conditions, using proprietary technologies such as PharmFi...
07-07 11:00
Aquestive Therapeutics Charts Cautious, Liquid Path Forward
Aquestive Therapeutics, Inc. (($AQST)) has held its Q1 earnings call. Read on f...
05-20 14:56
